updated 1/4/2011 7:16:03 AM ET 2011-01-04T12:16:03

DALLAS, Jan. 4, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Advanced Cell Technology Inc. (OTCBB:ACTC). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/lp/ACTC

Advanced Cell Technology Inc. (ACTC) is a biotechnology company focused on the development of cellular therapies for the treatment of rare and common diseases that impact millions of people worldwide. It applies stem cell-based technologies and other proprietary methods in the area of regenerative medicine to bring patient-specific therapies from the lab to the bedside. The Company is in the final stages of moving toward the initiation of phase I clinical trials for its Retinal Pigment Epithelial (RPE) program, which addresses a number of retinal degenerative disorders.

For only $19 a month, you can sign up for our real-time stock alert service.  Click here to join now: http://www.pennystocklive.com/premium-membership/

In the report, the analyst notes:

"ACTC announced that it was cleared by the U.S. Food and Drug Administration (FDA) to test a therapy made from embryonic stem cells in patients with macular degeneration, a leading cause of blindness. The Company is now allowed to initiate a phase I/II multicenter clinical trial to treat patients with the so-called dry form of macular degeneration.

"ACTC Thursday closed above its 13-day moving average. This is generally considered to be an indication of a bullish trend."

To read the entire report visit: www.microstockprofit.com/lp/ACTC

See what investors are saying about ACTC at http://www.stockhideout.com

Get breaking news on ACTC at http://thestockmarketwatch.com/

MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com

MicroStockProfit.com Disclosure

MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.

CONTACT: MicroStockProfit.com
         Brian Johnson

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved


Discussion comments


Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 3.79%
$30K home equity loan FICO 4.99%
$75K home equity loan FICO 4.69%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.83%
Cash Back Cards 17.80%
Rewards Cards 17.18%
Source: Bankrate.com